{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:41:49Z","timestamp":1790203309632,"version":"4.1.0"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2009,2,20]],"date-time":"2009-02-20T00:00:00Z","timestamp":1235088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["openorthopaedicsjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOORTHJ"],"published-print":{"date-parts":[[2009,2,20]]},"abstract":"<jats:p>Raloxifene, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium. <\/jats:p>\n                <jats:p>This is a review article summarizing its mechanism, effects on bone and its applicability in traumatology clinical practice. In postmenopausal osteoporosis, this drug has been proven to decrease accelerated bone turnover, increase bone mineral density (BMD), and to structurally recover bone, decreasing the risk of vertebral fractures and the risk of non-vertebral fractures in patients with previous, severe vertebral fractures. Moreover, raloxifene appears to lower the risk of invasive breast cancer. Raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis.<\/jats:p>\n                <jats:p>We can therefore conclude that raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis, while reducing the risk of breast cancer when used at the indicated dose of 60 mg\/day and with a low incidence of side effects.<\/jats:p>","DOI":"10.2174\/1874325000903010014","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T17:10:16Z","timestamp":1235754616000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology Practice"],"prefix":"10.2174","volume":"3","author":[{"given":"Jose R. Caeiro","family":"Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Vaquero","family":"Cervino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Rentero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Calvo","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Oteo","family":"\u00c1lvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Casillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1575-0922(03)74488-X","volume":"50","author":"Mu\u00f1oz-Torres M","year":"2003","unstructured":"Mu\u00f1oz-Torres M, Alonso G, Mezquita RP. \n                Prevenci\u00f3n y tratamiento de la osteoporosis \n                Endocrinol Nutr  \n                2003; \n                50\n               : 1-7.","journal-title":"Endocrinol Nutr"},{"key":"refR2","first-page":"S1","volume":"167","author":"Brown JP","year":"2002","unstructured":"Brown JP, Josse RG. \n                Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada \n                Can Med Assoc J  \n                2002; \n                167\n                (Suppl 10)\n                : S1-S34.","journal-title":"Can Med Assoc J"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/bmj.309.6960.1017b","volume":"309","author":"Stevenson JC","year":"1994","unstructured":"Stevenson JC, Baum M. \n                Hormone replacement therapy. Should be used selectively \n                BMJ  \n                1994; \n                309\n                (6948)\n                : 191-2.","journal-title":"BMJ"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF01622195","volume":"4","author":"Hillard TC","year":"1994","unstructured":"Hillard TC, Whitcroft SJ, Marsh MS, et al. \n                Long-term effects of transdermal and oral hormone replacement therapy on postmeno-pausal bone loss \n                Osteoporos Int  \n                1994; \n                4\n                (6)\n                : 341-8.","journal-title":"Osteoporos Int"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJM199403103301015","volume":"330","author":"Kanis JA","year":"1994","unstructured":"Kanis JA, Stevenson JC. \n                Effect of estrogen therapy on bone density in elderly women \n                N Engl J Med  \n                1994; \n                330\n                (10)\n                : 715-6.\n                \n                \n             author reply","journal-title":"N Engl J Med"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJM199310143291601","volume":"329","author":"Felson DT","year":"1993","unstructured":"Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. \n                The effect of postmenopausal estrogen therapy on bone density in elderly women \n                N Engl J Med  \n                1993; \n                329\n                (16)\n                : 1141-6.","journal-title":"N Engl J Med"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4321\/S1137-66272003000600009","volume":"26","author":"Landa MC","year":"2003","unstructured":"Landa MC. \n                Papel de la terapia hormonal sustitutiva, en la prevenci\u00f3n y tratamiento de la osteoporosis menop\u00e1usica \n                An Sist Sanit Navar  \n                2003; \n                26\n                (Suppl 3)\n                : 99-105.","journal-title":"An Sist Sanit Navar"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","volume":"289","author":"Chlebowski RT","year":"2003","unstructured":"Chlebowski RT, Hendrix SL, Langer RD, et al. \n                WHI Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women the Women's Health Initiative Randomized Trial \n                JAMA  \n                2003; \n                289\n                (24)\n                : 3243-53.","journal-title":"JAMA"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","volume":"362","author":"Beral V","year":"2003","unstructured":"Beral V. \n                Million Women Study Collaborators Breast cancer and hormone-replacement therepy in the Million Women Study \n                Lancet  \n                2003; \n                362\n               : 419-27.","journal-title":"Lancet"},{"key":"refR10","first-page":"531","volume":"8","author":"Kauffman RF","year":"1995","unstructured":"Kauffman RF, Bryant HU. \n                Selective estrogen receptor modulators \n                Drug News Perspect  \n                1995; \n                8\n                (9)\n                : 531-9.","journal-title":"Drug News Perspect"},{"key":"refR11","first-page":"670","author":"Palacios S","year":"1999","unstructured":"Palacios S. \n                Moduladores selectivos of the receptores estrogenicos \n                Rev Clin Esp  \n                1999; \n               670-74.","journal-title":"Rev Clin Esp"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","volume":"348","author":"Riggs BL","year":"2003","unstructured":"Riggs BL, Hartmann LC. \n                Selective estrogen-receptor modulators Mechanisms of action and application to clinical practice \n                N Engl J Med  \n                2003; \n                348\n                (12)\n                : 618-29.","journal-title":"N Engl J Med"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/BMM:3:1:019","volume":"3","author":"Petersen NM","year":"2005","unstructured":"Petersen NM, Briggs AL. \n                Selective estrogen receptor modulators \n                Clin Rev Bone Miner Metab  \n                2005; \n                3\n                (1)\n                : 19-30.","journal-title":"Clin Rev Bone Miner Metab"},{"key":"refR14","unstructured":"Zanchetta JR, Talbot JR. \n                Raloxifeno In: \n                Osteoporsis.  ED. \n                 Buenos Aires (Argentina): Ed, Panamericana 2001; pp. \n                \n                \n                                \n                359-65."},{"key":"refR15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0960-894X(96)00141-2","volume":"6","author":"Grese TA","year":"1996","unstructured":"Grese TA, Sluka JP, Bryant HU, et al. \n                Benzopyran selective estrogen receptor modulators (SERMS): Pharmacological effects and structural correlation with raloxifene \n                Bioorg Med Chem Lett  \n                1996; \n                6\n               : 903-08.","journal-title":"Bioorg Med Chem Lett"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01771666","volume":"14","author":"Bryant HU","year":"1996","unstructured":"Bryant HU, Glasebrook AL, Yang NN, Sato M. \n                A pharmacologic review of raloxifene \n                J Bone Miner Metab  \n                1996; \n                14\n               : 1-9.","journal-title":"J Bone Miner Metab"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1621100","volume":"257","author":"Jilka RL","year":"1992","unstructured":"Jilka RL, Hangoc G, Girasole G, et al. \n                Increased osteoclast development after estrogen loss: Medication by interleukin-6 \n                Science  \n                1992; \n                257\n               : 88-91.","journal-title":"Science"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","volume":"273","author":"Yang NN","year":"1996","unstructured":"Yang NN, Venugopalan M, Hardikar S, Glasebrook A. \n                Identification of an estrogen response element activated by metabolites of \u03b2-estradiol and raloxifene \n                Science  \n                1996; \n                273\n                (5279)\n                : 1222-25.","journal-title":"Science"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1210\/jc.2004-0795","volume":"89","author":"Gianni W","year":"2004","unstructured":"Gianni W, Ricci A, Gazzaniga P, et al. \n                Raloxifene modulates inter-leukin-6 and tumor necrosis factor-{alpha} synthesis in vivo: Re-sults from a pilot clinical study \n                J Clin Endocrinol Metab  \n                2004; \n                89\n                (12)\n                : 6097-99.","journal-title":"J Clin Endocrinol Metab"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0092-8674(87)90581-2","volume":"51","author":"Kumar V","year":"1987","unstructured":"Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. \n                Functional domains of the human estrogen receptor \n                Cell  \n                1987; \n                51\n               : 941-51.","journal-title":"Cell"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S8756-3282(03)00236-9","volume":"33","author":"Heaney RP","year":"2003","unstructured":"Heaney RP. \n                Is the paradigm shifting? \n                Bone  \n                2003; \n                33\n               : 457-65.","journal-title":"Bone"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1210\/endo.135.5.7956922","volume":"135","author":"Turner CH","year":"1994","unstructured":"Turner CH, Sato M, Bryant HU. \n                Raloxifene preserves bone strength and bone mass in ovariectomized rats \n                Endocrinology  \n                1994; \n                135\n                (5)\n                : 2001-5.","journal-title":"Endocrinology"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1210\/endo.137.10.8828469","volume":"137","author":"Evans GL","year":"1996","unstructured":"Evans GL, Bryant HU, Magee DE, et al. \n                Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariec-tomized rats with established osteopenia \n                Endocrinology  \n                1996; \n                137\n                (10)\n                : 4139-4.","journal-title":"Endocrinology"},{"key":"refR24","first-page":"445","volume":"11","author":"Jerome CP","year":"1996","unstructured":"Jerome CP, Lees CJ. \n                Raloxifene increases bone mass and reduces bone turnover in ovariectomized cynomolgus monkeys \n                J Bone Miner Res  \n                1996; \n                11\n               : 445-1.","journal-title":"J Bone Miner Res"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"Ettinger B","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al. \n                For the multiple outcomes of raloxifene evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial \n                JAMA  \n                1999; \n                282\n                (7)\n                : 637-45.","journal-title":"JAMA"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","volume":"13","author":"Lufkin EG","year":"1998","unstructured":"Lufkin EG, Whitaker MD, Nickelsen T, et al. \n                Treatment of estab-lished postmenopausal osteoporosis with raloxifene: a randomized trial \n                J Bone Miner Res  \n                1998; \n                13\n               : 1747-54.","journal-title":"J Bone Miner Res"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"Delmas PD","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, et al. \n                Effects of Raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women \n                N Engl J Med  \n                1997; \n                337\n                (23)\n                : 1641-47.","journal-title":"N Engl J Med"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","volume":"12","author":"Bjarnason NH","year":"2001","unstructured":"Bjarnason NH, Sarkar S, Duong T. \n                Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in post-menopausal osteoporosis \n                Osteoporos Int  \n                2001; \n                12\n               : 922-30.","journal-title":"Osteoporos Int"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","volume":"17","author":"Sarkar S","year":"2002","unstructured":"Sarkar S, Mitlak BH, Wong M, et al. \n                Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy \n                J Bone Miner Res  \n                2002; \n                17\n                (1)\n                : 1-10.","journal-title":"J Bone Miner Res"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"Cummings SR","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al. \n                Effect of alendro-nate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial \n                JAMA  \n                1998; \n                280\n                (24)\n                : 2077-82.","journal-title":"JAMA"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"112","author":"Cummings SR","year":"2002","unstructured":"Cummings SR, Karpf DB, Harris F, et al. \n                Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antirresorptive drugs \n                Am J Med  \n                2002; \n                112\n               : 281-9.","journal-title":"Am J Med"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","volume":"7","author":"Watts NB","year":"2004","unstructured":"Watts NB, Cooper C, Lindsay R, et al. \n                R elationship between changes in bone mineral density and vertebral fracture risk associated with risedronate \n                J Clin Densitom  \n                2004; \n                7\n               : 255-61.","journal-title":"J Clin Densitom"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00002281-200207000-00017","volume":"14","author":"Gluck O","year":"2002","unstructured":"Gluck O, Maricic M. \n                Raloxifene: Recent information on skeletal and non-skeletal effects \n                Curr Opin Reumatol  \n                2002; \n                14\n               : 429-32.","journal-title":"Curr Opin Reumatol"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","volume":"33","author":"Kanis JA","year":"2003","unstructured":"Kanis JA, Johnell O, Black DM, et al. \n                Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the multiple outcomes of raloxifene evaluation trial \n                Bone  \n                2003; \n                33\n                (3)\n                : 293-300.","journal-title":"Bone"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","volume":"162","author":"Maricic M","year":"2002","unstructured":"Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. \n                Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis \n                Arch Intern Med  \n                2002; \n                162\n                (10)\n                : 1140-3.","journal-title":"Arch Intern Med"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"Delmas P","year":"2003","unstructured":"Delmas P, Genant HK, Crans G, et al. \n                Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial \n                Bone  \n                2003; \n                33\n                (4)\n                : 522-32.","journal-title":"Bone"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"Cummings SR","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, et al. \n                The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial \n                JAMA  \n                1999; \n                281\n               : 2189-97.","journal-title":"JAMA"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/BF02383389","volume":"12","author":"Sato M","year":"1994","unstructured":"Sato M, Glasebrook AL, Bryant HU. \n                Raloxifene: a selective estrogen receptor modulator \n                J Bone Miner Metab  \n                1994; \n                12\n                (S2)\n                : S9-S20.","journal-title":"J Bone Miner Metab"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"Vogel VG","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, et al. \n                Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial \n                JAMA  \n                2006; \n                295\n               : 2727-41.","journal-title":"JAMA"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1001\/archinte.1993.00410190045006","volume":"153","author":"Bass KM","year":"1993","unstructured":"Bass KM, Newschaffer CJ, Klag MJ, Bush TL. \n                Plasma lipoprotein levels as predictors of cardiovascular death in women \n                Arch Intern Med  \n                1993; \n                153\n               : 2209-16.","journal-title":"Arch Intern Med"},{"key":"refR41","unstructured":"Evista- U.S. Food and Drug Administration [online]. \n                Available from URL:http:\/\/www.fda.gov\/cder\/foi\/label\/2007\/022042lbl.pdf  \n                 [Accessed 2007, Sep 28];"},{"key":"refR42","unstructured":"Evista-EU Summary of Product Characteristics \n                Available from URL: http:\/\/emea.europa.eu\/humandocs\/PDFs\/EPAR\/Evista\/H-184-PI-en.pdf  \n                 [Accessed 2007 Sep 28];"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","volume":"160","author":"Johnston CC Jr","year":"2000","unstructured":"Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. \n                Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials \n                Arch Intern Med  \n                2000; \n                160\n               : 3444-50.","journal-title":"Arch Intern Med"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"Martino S","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, et al. \n                Continuing Outcomes Relevant Evista\u00ae: incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene \n                J Natl Cancer Inst  \n                2004; \n                96\n               : 1751-61.","journal-title":"J Natl Cancer Inst"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","volume":"21","author":"Martino S","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA, et al. \n                Safety assessement of raloxifene over eight years in a clinical trial setting \n                Curr Med Res Opin  \n                2005; \n                21\n                (9)\n                : 1441-52.","journal-title":"Curr Med Res Opin"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"Barrett-Connor E","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al. \n                Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women \n                N Engl J Med  \n                2006; \n                355\n               : 125-37.","journal-title":"N Engl J Med"}],"container-title":["The Open Orthopaedics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openorthopaedicsjournal.com\/contents\/volumes\/V3\/TOORTHJ-3-14\/TOORTHJ-3-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openorthopaedicsjournal.com\/contents\/volumes\/V3\/TOORTHJ-3-14\/TOORTHJ-3-14.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openorthopaedicsjournal.com\/contents\/volumes\/V3\/TOORTHJ-3-14\/TOORTHJ-3-14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T10:24:08Z","timestamp":1553250248000},"score":1,"resource":{"primary":{"URL":"https:\/\/openorthopaedicsjournal.com\/VOLUME\/3\/PAGE\/14\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2,20]]}},"alternative-id":["TOORTHJ-3-14"],"URL":"https:\/\/doi.org\/10.2174\/1874325000903010014","relation":{},"ISSN":["1874-3250"],"issn-type":[{"value":"1874-3250","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2008-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-1-5","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-1-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-2-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}